Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management "should provide some much-needed breathing room" for the AIM-listed pharma group, said Stifel analysts.
"This, along with the business looking to lower its cost base by circa 10%, will help strengthen the balance sheet and support achieving cash flow breakeven by 2025 year-end," they stated, adding that the company is "on track for 2024".
Stifel's comments follow a Thursday trading update from Shield, which showed that the company is on track to meet its full-year 2024 revenue target of $31.5 million.
According to Stifel, strong sales growth for iron deficiency drug ACCRUFeR will be the key ingredient to Shield hitting mid-term targets.
So far so good- Shield reported strong sales of ACCRUFeR in October, bolstered by an increase in the net selling price to over $225 per prescription, up from $167 in the third quarter of 2024.
Stifel has a 3.5p per share price target on Shield shares against a Thursday price of 2.88p.